Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
TD beat chemotherapy after failure of hormonal therapy in HER-2 low and ultra low. Wait for the indication.
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01
Author(s): Aditya Bardia, MD, MPH1,2; Komal Jhaveri, MD, FACP3,4; Seock-Ah Im, MD, PhD5; Sonia Pernas, MD, PhD6; Michelino De Laurentiis, MD7; Shusen Wang, MD8; Noelia Martínez Jañez, MD, PhD9; Giuliano Borges, MD10; David W. Cescon, MD, PhD11; Masaya Hattori, MD12; Yen-Shen Lu, MD, PhD13; Erika Hamilton, MD14; Qingyuan Zhang, MD, PhD15; Junji Tsurutani, MD, PhD16; Kevin Kalinsky, MD, MS17; Pedro Emanuel Rubini Liedke, MD18,19,20; Lu Xu, PhD21; Rick M. Fairhurst, MD, PhD21; Sabrina Khan, MD, MPH21; Neelima Denduluri, MD21; Hope S. Rugo, MD22; Binghe Xu, MD, PhD23; Barbara Pistilli, MD24;
Source: https://doi.org/10.1200/JCO.24.00920
Dr. Anjan Patel's Thoughts
Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.
PURPOSE
The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer.
METHODS
Adult patients with inoperable/metastatic HR+/HER2‒ breast cancer, who had disease progression on endocrine therapy, for whom endocrine therapy was unsuitable, and had received one to two previous lines of chemotherapy in the inoperable/metastatic setting, were randomly assigned 1:1 to Dato-DXd (6 mg/kg once every 3 weeks) or ICC (eribulin/vinorelbine/capecitabine/gemcitabine). Dual primary end points were progression-free survival (PFS) by blinded independent central review (BICR) and overall survival (OS).
RESULTS
Patients were randomly assigned to Dato-DXd (n = 365) or ICC (n = 367). Dato-DXd significantly reduced the risk of progression or death versus ICC (PFS by BICR hazard ratio [HR], 0.63 [95% CI, 0.52 to 0.76]; P < .0001). Consistent PFS benefit was observed across subgroups. Although OS data were not mature, a trend favoring Dato-DXd was observed (HR, 0.84 [95% CI, 0.62 to 1.14]). The rate of grade ≥3 treatment-related adverse events (TRAEs) with Dato-DXd was lower than ICC (20.8% v 44.7%). The most common TRAEs (any grade; grade ≥3) were nausea (51.1%; 1.4%) and stomatitis (50%; 6.4%) with Dato-DXd and neutropenia (grouped term, 42.5%; 30.8%) with ICC.
CONCLUSION
Patients receiving Dato-DXd had statistically significant and clinically meaningful improvement in PFS and a favorable and manageable safety profile, compared with ICC. Results support Dato-DXd as a novel treatment option for patients with inoperable/metastatic HR+/HER2‒ breast cancer who have received one to two previous lines of chemotherapy in this setting.
Author Affiliations
1Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA; 2Massachusetts General Hospital Cancer Center, Boston, MA; 3Memorial Sloan Kettering Cancer Center, New York, NY; 4Weill Cornell Medical College, New York, NY; 5Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul National University, Seoul, Republic of Korea; 6Institut Català d’Oncologia-IDIBELL, L’Hospitalet, Barcelona, Spain; 7Istituto Nazionale Tumori Napoli IRCCS “Fondazione Pascale”, Napoli, Italy; 8Cancer Center of Sun Yat-sen University, Guangzhou, China; 9Ramón y Cajal University Hospital, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain; 10Catarina Pesquisa Clínica, Santa Catarina, Brazil; 11Princess Margaret Cancer Centre/UHN, Toronto, ON, Canada; 12Aichi Cancer Center, Nagoya, Japan; 13National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; 14Sarah Cannon Research Institute, Nashville, TN; 15Harbin Medical University Cancer Hospital, Harbin, China; 16Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan; 17Winship Cancer Institute at Emory University, Atlanta, GA; 18Hospital das Clínicas de Porto Alegre (HCPA), Porto Alegre, Brazil; 19UPCO—Pesquisa Clinica em Oncologia, Porto Alegre, Brazil; 20Oncoclinicas Porto Alegre, Porto Alegre, Brazil; 21AstraZeneca, Gaithersburg, MD; 22University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; 23National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; 24Gustave Roussy Cancer Center, Villejuif, France;Related Articles
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
MammaPrint did not predict distant recurrence, but it did predict patients who may benefit from extended hormonal therapy. We do have breast index, so now we have options. Breast index can predict the possibility of recurrence though by helping to determine the level of risk.
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
This study confirms what we saw in initial reports showing the addition of pembro increasing the rate of ypathological complete response (ypCR’s) in the neoadjuvant setting for triple-negative breast cancer (TNBC). New data shows a 5% improvement (87 vs 82%) in overall survival (OS) with the quadruplet. Higher gains but at higher cost of toxicity. The fact that adjuvant intraosseous (IO) does not seem to improve outcomes, but neoadjuvant chemo+IO does show intact tumor-immune interactions to create maximum treatment effectiveness is most likely real. Of note, this seems mostly independent of programmed death-ligand 1 (PDL1) status.
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
Adding Inavolisib to CKD4/6 inhibitor and AI improved progression-free survival (almost doubled 15 vs 7m) but toxicity was higher still in the single digits (hyperglycemia, diarrhea, stomatitis… all less than 6% G3/4).
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial
Well done study showing a 20% decrease in recurrence risk when using dose dense therapy [EC]/D compared to conventional dose [FEC]/D. Sometimes it is worth it to push.
